prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics
novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain a/viet nam/1194/2004 (h5n1) - influenza, human - vaccines - active immunisation against h5n1 subtype of influenza a virus.; this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain.; prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.
covid-19 vaccine (inactivated, adjuvanted) valneva
valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vaccines - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age. the use of this vaccine should be in accordance with official recommendations.
websters bursavac k infectious bursal disease vaccine (oil adjuvanted inactivated v877 strain virus)
zoetis australia pty ltd - infectious bursal disease virus (ibd) strain v877 - misc. vaccines or anti sera - infectious bursal disease virus (ibd) strain v877 vaccine-viral active 0.0 p - immunotherapy - fowl - infectious bursal disease | vaccine | bursal disease | equine rotavirus
respisure mh/hps vaccine (inactivated)
zoetis - vaccine - mycoplasma hyopneum.+vaccine - glassers - parenteral liquid/solution/suspension - vaccine - pigs | boar | gilt | piglet | sow | swine - glassers disease | growth suppression | haemophilus parasuis serovar 13 | haemophilus parasuis serovar 4 | haemophilus parasuis serovar 5 | lung lesions | mycoplasma hyopneumoniae | polyserositis | respiratory disease | reduction of lung lesions | respiratory disease | swine enzootic pneumonia
protech c2i canine coronavirus & leptospira copenhageni killed vaccine
boehringer ingelheim animal health australia pty. ltd. - leptospira icterohaemorrhagiae antigen; canine coronavirus vaccine - antigen - misc. vaccines or anti sera - leptospira icterohaemorrhagiae antigen vaccine-antigen active 1.0 rp; canine coronavirus vaccine - antigen vaccine-viral active 1.62 rp - immunotherapy - dog - over 6 weeks old - canine adenovirus - type 1 | canine adenovirus - type 2 | canine coronavirus | canine distemper | canine parainfluenza | canine parvovirus | leptospira icterohaemorrhagiae | parvovirus
vaxitet vaccine 5 ml
incepta pharmaceuticals ltd., vaccine division - adsorbed tetanus vaccine - vaccine - 40 %/.5 ml
vaxitet vaccine
incepta pharmaceuticals ltd., vaccine division - adsorbed tetanus vaccine - vaccine - 5 lf/.5 ml
hepa-b vaccine for adult
incepta pharmaceuticals ltd., vaccine division - hepatitis b vaccine - vaccine - 20 mcg/ml
hepa-b vaccine for pediatric
incepta pharmaceuticals ltd., vaccine division - hepatitis b vaccine - vaccine - 10 mcg/ml
measles vaccine
incepta pharmaceuticals ltd., vaccine division - measles vaccine (live) - vaccine - .5 ml